Recent Advances in Chemotherapy of Gastric Cancer / 대한내과학회지
Korean Journal of Medicine
; : 417-426, 2012.
Article
in Ko
| WPRIM
| ID: wpr-25223
Responsible library:
WPRO
ABSTRACT
Surgery is the best and the only treatment modality for cure if a patient has resectable gastric cancer. The outcome can be improved by a strategy of perioperative (neoadjuvant or adjuvant) chemotherapy or chemoradiotherapy. Whereas, advanced gastric cancer is treated primarily with chemotherapy; however, no chemotherapy regimen has been considered a standard. First-line chemotherapy generally includes fluoropyrimidine and cisplatin, sometimes with the addition of a third drug (epirubicin or docetaxel). In second-line setting, chemotherapy with single-agent irinotecan or docetaxel has emerged as a new standard of care. With improved understanding of the biology of gastric cancer and the identification of key signaling pathways, a number of promising molecularly-targeted agents have been studied that broaden the therapeutic options in the future. Regardless of the extent of disease or treatment modality, a multidisciplinary team approach is always desired since it can provide best treatment options for the patients.
Key words
Full text:
1
Database:
WPRIM
Main subject:
Stomach Neoplasms
/
Biology
/
Camptothecin
/
Cisplatin
/
Taxoids
/
Standard of Care
/
Chemoradiotherapy
Limits:
Humans
Language:
Ko
Journal:
Korean Journal of Medicine
Year:
2012
Document type:
Article